Ceftibuten-clavulanate (CTB-CLA) is a novel β-lactam–β-lactamase combination with potential utility for the management of urinary tract infections caused by extended-spectrum-β-lactamase (ESBL)-producing organisms. We examined the pharmacodynamics of the combination against 25
Enterobacteriaceae
expressing β-lactamases (CTX-M, TEM, and SHV wild types and SHV-ESBL) in the murine thigh infection model.